MUNICH — The investigational antiplatelet drug prasugrel was particularly effective for cutting ischemic events in patients with diabetes and relatively less effective in patients without diabetes in a prespecified analysis of the more than 13,000 patients in the drug's pivotal trial.
PREVIEW